Morten Høgild Pedersen1,2, Mads Vandsted Svart1,2, Janne Lebeck3, Martin Bidlingmaier4, Hans Stødkilde-Jørgensen5,2, Steen Bønløkke Pedersen1,2, Niels Møller1,2, Niels Jessen6, Jens O L Jørgensen1,2. 1. Medical Research Laboratory, Department of Endocrinology and Internal Medicine. 2. Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark. 3. Department of Biomedicine and. 4. Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität, 80336 Munich, Germany. 5. The MR Research Center, and. 6. Department of Clinical Pharmacology, Aarhus University Hospital 8000 Aarhus, Denmark.
Abstract
CONTEXT: Insulin resistance and metabolic inflexibility are features of obesity and are amplified by fasting. Growth hormone (GH) secretion increases during fasting and GH causes insulin resistance. OBJECTIVE: To study the metabolic effects of GH blockade during fasting in obese subjects. SUBJECTS AND METHODS: Nine obese males were studied thrice in a randomized design: (1) after an overnight fast (control), (2) after 72 hour fasting (fasting), and (3) after 72 hour fasting with GH blockade (pegvisomant) [fasting plus GH antagonist (GHA)]. Each study day consisted of a 4-hour basal period followed by a 2-hour hyperinsulinemic, euglycemic clamp combined with indirect calorimetry, assessment of glucose and palmitate turnover, and muscle and fat biopsies. RESULTS: GH levels increased with fasting (P < 0.01), and the fasting-induced reduction of serum insulin-like growth factor I was enhanced by GHA (P < 0.05). Fasting increased lipolysis and lipid oxidation independent of GHA, but fasting plus GHA caused a more pronounced suppression of lipid intermediates in response to hyperinsulinemic, euglycemic clamp. Fasting-induced insulin resistance was abrogated by GHA (P < 0.01) primarily due to reduced endogenous glucose production (P = 0.003). Fasting plus GHA also caused elevated glycerol levels and reduced levels of counterregulatory hormones. Fasting significantly reduced the expression of antilipolytic signals in adipose tissue independent of GHA. CONCLUSIONS: Suppression of GH activity during fasting in obese subjects reverses insulin resistance and amplifies insulin-stimulated suppression of lipid intermediates, indicating that GH is an important regulator of substrate metabolism, insulin sensitivity, and metabolic flexibility also in obese subjects.
CONTEXT: Insulin resistance and metabolic inflexibility are features of obesity and are amplified by fasting. Growth hormone (GH) secretion increases during fasting and GH causes insulin resistance. OBJECTIVE: To study the metabolic effects of GH blockade during fasting in obese subjects. SUBJECTS AND METHODS: Nine obese males were studied thrice in a randomized design: (1) after an overnight fast (control), (2) after 72 hour fasting (fasting), and (3) after 72 hour fasting with GH blockade (pegvisomant) [fasting plus GH antagonist (GHA)]. Each study day consisted of a 4-hour basal period followed by a 2-hour hyperinsulinemic, euglycemic clamp combined with indirect calorimetry, assessment of glucose and palmitate turnover, and muscle and fat biopsies. RESULTS: GH levels increased with fasting (P < 0.01), and the fasting-induced reduction of serum insulin-like growth factor I was enhanced by GHA (P < 0.05). Fasting increased lipolysis and lipid oxidation independent of GHA, but fasting plus GHA caused a more pronounced suppression of lipid intermediates in response to hyperinsulinemic, euglycemic clamp. Fasting-induced insulin resistance was abrogated by GHA (P < 0.01) primarily due to reduced endogenous glucose production (P = 0.003). Fasting plus GHA also caused elevated glycerol levels and reduced levels of counterregulatory hormones. Fasting significantly reduced the expression of antilipolytic signals in adipose tissue independent of GHA. CONCLUSIONS: Suppression of GH activity during fasting in obese subjects reverses insulin resistance and amplifies insulin-stimulated suppression of lipid intermediates, indicating that GH is an important regulator of substrate metabolism, insulin sensitivity, and metabolic flexibility also in obese subjects.
Authors: Silvana Duran-Ortiz; Kathryn L Corbin; Ishrat Jahan; Nicholas B Whitticar; Sarah E Morris; Ania N Bartholomew; Kira G Slepchenko; Hannah L West; Ibiagbani Mercy Max Harry; Edward O List; John J Kopchick; Craig S Nunemaker Journal: Am J Physiol Endocrinol Metab Date: 2021-05-03 Impact factor: 5.900
Authors: José C E Serrano; Juan Antonio Baena-Fustegueras; Meritxell Martin-Gari; Helene Rassendren; Anna Cassanye; Alba Naudí; Carolina López-Cano; Enric Sánchez; María Cruz de la Fuente-Juárez; Fernando Herrerías González; Jorge J Olsina Kissler; Albert Lecube; Manuel Portero-Otín Journal: Obesity (Silver Spring) Date: 2019-05-21 Impact factor: 5.002
Authors: Jonathan M Dreyfuss; Yixing Yuchi; Xuehong Dong; Vissarion Efthymiou; Hui Pan; Donald C Simonson; Ashley Vernon; Florencia Halperin; Pratik Aryal; Anish Konkar; Yinong Sebastian; Brandon W Higgs; Joseph Grimsby; Cristina M Rondinone; Simon Kasif; Barbara B Kahn; Kathleen Foster; Randy Seeley; Allison Goldfine; Vera Djordjilović; Mary Elizabeth Patti Journal: Nat Commun Date: 2021-11-29 Impact factor: 17.694
Authors: Anders Hostrup Larsen; Henrik Wiggers; Ole Lindgård Dollerup; Nichlas Riise Jespersen; Nils Henrik Hansson; Jørgen Frøkiær; Kim Brøsen; Helene Nørrelund; Hans Erik Bøtker; Niels Møller; Niels Jessen Journal: Cardiovasc Drugs Ther Date: 2020-08-08 Impact factor: 3.727
Authors: Astrid Johannesson Hjelholt; Kevin Y Lee; Mai Christiansen Arlien-Søborg; Steen Bønløkke Pedersen; John J Kopchick; Vishwajeet Puri; Niels Jessen; Jens Otto L Jørgensen Journal: Mol Metab Date: 2019-08-20 Impact factor: 7.422